Parkwalk Advisors and Cambridge Innovation Capital have backed the pet antibody therapeutics developer, a spinout of Wellcome Sanger Institute.

PetMedix, a UK-based pet-focused antibody treatment developer, closed a £27m ($37m) series B round yesterday that included patient capital fund Cambridge Innovation Capital (CIC) and Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group. Pharmaceutical and veterinary group Kyoritsu Holding and internet company Tencent also took part in the round, as did venture…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.